Skip to main content

Advertisement

Table 2 Predicted DDI types of drug pairs

From: Novel deep learning model for more accurate prediction of drug-drug interaction effects

Drug A Drug B DDI type (Drugbank v5.1.1)a Score (Drugbank v5.1.1) DDI type (new prediction)a Score (new prediction) Reference
Amodiaquine Pyrimethamine 100 0.999999762 86 0.999997854 DrugBank v 5.1.2
Amodiaquine Cholecalciferol 100 0.99999392 86 0.996211529 DrugBank v 5.1.2
Betrixaban Rivaroxaban 76 0.518932223 18 0.989234567 DrugBank v 5.1.2
Disopyramide Asenapine 24 0.775597036 72 0.984019518 https://www.pdr.net
Nefazodone Amoxapine 19 0.581683695 56 0.907319307 https://online.epocrates.com
Ulipristal Pentobarbital 99 0.999979138 104 0.902777851 https://www.pdr.net
Fingolimod Dronedarone 22 0.547105849 14 0.881702363 [21]
Trazodone Methylene blue 56 0.697363019 96 0.879396319 https://www.pdr.net
Fluorouracil Metronidazole 100 0.782166064 102 0.864007413 https://www.drugs.com
Tacrolimus Escitalopram 86 0.511624634 14 0.851550758 [22, 21]
Tacrolimus Citalopram 86 0.511636794 14 0.851546466 [22, 23]
Methadone Escitalopram 86 0.537029743 14 0.849954724 [22, 21]
  1. a 14: DRUG_A may increase the QTc-prolonging activities of DRUG_B
  2. 18: DRUG_A may increase the anticoagulant activities of DRUG_B
  3. 19: DRUG_A may increase the antihypertensive activities of DRUG_B
  4. 22: DRUG_A may increase the arrhythmogenic activities of DRUG_B
  5. 24: DRUG_A may increase the bradycardic activities of DRUG_B
  6. 56: DRUG_A may increase the serotonergic activities of DRUG_B
  7. 72: The risk or severity of QTc prolongation can be increased when DRUG_A is combined with DRUG_B
  8. 76: The risk or severity of bleeding can be increased when DRUG_A is combined with DRUG_B
  9. 86: The risk or severity of hypotension can be increased when DRUG_A is combined with DRUG_B
  10. 96: The risk or severity of serotonin syndrome can be increased when DRUG_A is combined with DRUG_B
  11. 99: The serum concentration of DRUG_A can be decreased when it is combined with DRUG_B
  12. 100: The serum concentration of DRUG_A can be increased when it is combined with DRUG_B
  13. 102: The serum concentration of the active metabolites of DRUG_A can be increased when DRUG_A is used in combination with DRUG_B
  14. 104: The therapeutic efficacy of DRUG_A can be decreased when used in combination with DRUG_B